Nutriband Inc (NTRB) - Total Liabilities
Based on the latest financial reports, Nutriband Inc (NTRB) has total liabilities worth $868.45K USD as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NTRB shareholders equity momentum to track the company's year-over-year net asset growth rate.
Nutriband Inc - Total Liabilities Trend (2016–2026)
This chart illustrates how Nutriband Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Nutriband Inc to measure how efficiently the company converts operating cash flow to free cash.
Nutriband Inc Competitors by Total Liabilities
The table below lists competitors of Nutriband Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SJM Co Ltd
KO:123700
|
Korea | ₩55.39 Billion |
|
JNK Heaters Co. Ltd
KQ:126880
|
Korea | ₩143.42 Billion |
|
Konsortium Transnasional Bhd
KLSE:4847
|
Malaysia | RM191.01 Million |
|
Molecure S.A.
WAR:MOC
|
Poland | zł9.24 Million |
|
Lider Faktoring AS
IS:LIDFA
|
Turkey | TL7.88 Billion |
|
Namibia Critical Metals Inc
V:NMI
|
Canada | CA$763.06K |
|
IFCA MSC Bhd
KLSE:0023
|
Malaysia | RM31.11 Million |
|
Samwha Elec
KO:011230
|
Korea | ₩55.59 Billion |
Liability Composition Analysis (2016–2026)
This chart breaks down Nutriband Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NTRB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nutriband Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nutriband Inc (2016–2026)
The table below shows the annual total liabilities of Nutriband Inc from 2016 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-01-31 | $868.45K | -16.58% |
| 2025-01-31 | $1.04 Million | -3.51% |
| 2024-01-31 | $1.08 Million | +22.13% |
| 2023-01-31 | $883.39K | +0.34% |
| 2022-01-31 | $880.38K | -68.73% |
| 2021-01-31 | $2.82 Million | +39.22% |
| 2020-01-31 | $2.02 Million | +401.81% |
| 2019-01-31 | $403.01K | +828.78% |
| 2018-01-31 | $43.39K | +196.83% |
| 2017-01-31 | $14.62K | +23.88% |
| 2016-01-31 | $11.80K | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more